Editorial: Next generation MSC therapy manufacturing, potency and mechanism of action analysis

Raghavan Chinnadurai; Sowmya Viswanathan; Guido Moll

doi:10.3389/fimmu.2023.1192636

Editorial: Next generation MSC therapy manufacturing, potency and mechanism of action analysis

Front Immunol. 2023 Apr 21:14:1192636. doi: 10.3389/fimmu.2023.1192636. eCollection 2023.

Authors

Raghavan Chinnadurai¹, Sowmya Viswanathan^{2

3

4}, Guido Moll^{5

6

7}

Affiliations

¹ Department of Biomedical Sciences, Mercer University School of Medicine, Savannah, GA, United States.
² Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada.
³ Krembil Research Institute, University Health Network, Toronto, ON, Canada.
⁴ Institute of Biomedical Engineering, Division of Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
⁵ BIH Center for Regenerative Therapies (BCRT), Berlin, Germany.
⁶ Berlin-Brandenburg School for Regenerative Therapies (BSRT), Berlin, Germany.
⁷ Department of Nephrology and Internal Intensive Care Medicine, all Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health (BIH), Berlin, Germany.

No abstract available

Keywords: and regeneration; cell product manufacturing; cell therapy; immunomodulation; mechanism of action (MOA); mesenchymal stromal/stem cells (MSC); potency analysis; safety and efficacy.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Immunomodulation*
Mesenchymal Stem Cells*

Grants and funding

GM’s contributions were made possible by the German Research Foundation/Deutsche Forschungsgemeinschaft (DFG; EX-PAND-PD CA2816/1-1) and the German Federal Ministry of Education and Research (BMBF) funding through the BSRT (GSC203) and BCRT, and in part by funding from the European Union’s Horizon 2020 research and innovation program under grant agreements No. 733006 (PACE) and No. 779293 (HIPGEN).